A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
ABB, Buenos Aires F.D. C1199ABB, Argentina
CABA, 1426, Argentina
North Ballarat, Victoria 33500, Australia
Hubei Sheng, Hubei 430079, China
Kashiwa-shi, Chiba 2778577, Japan
Kitakyushu-shi, Fukuoka 8078556, Japan
Sakai-shi, Osaka 5918555, Japan
Kitaadachigun, Saitama 3620806, Japan
Bunkyo-ku, Tokyo 1138431, Japan
Bunkyo-ku, Tokyo 1138603, Japan
Chuo-ku, Tokyo 1040045, Japan
Chuo-ku, Tokyo 5418567, Japan
Hato Rey, 00917, Puerto Rico
Majadahonda - Madrid, 28222, Spain